Market Research Report
Biosimilars: US Payer Insights 2020
|Published by||FirstWord||Product code||940403|
Delivery time: 1-2 business days
|Biosimilars: US Payer Insights 2020|
|Published: May 7, 2020||Content info:||
What do payers see as unlocking the sluggish US biosimilar market?
Despite the availability of biosimilar versions of Avastin, Herceptin and Rituxan, payers are not pleased with the development within this sector. Insufficient discounts on biosimilar drugs and aggressive contracting strategies by originator companies together weaken the appeal of biosimilars. Payers also cite obstacles such as an inability to extrapolate biosimilar use across all indications of the reference product. With biosimilar Humira and Enbrel on the horizon the potential for significant savings is recognized, so what insights do payers have for biosimilar manufacturers wanting to make a breakthrough?
Understanding the issues that are shaping US payer behaviour is critical. That is why we have interviewed in-depth 8 experienced US payers to reveal in ‘Biosimilars: US Payer Insights 2020’ their attitudes, needs and the practical steps pharma companies can take to address their concerns.
"If companies were making efforts to understand our goals, I think that biosimilars would have come to the market with a higher discount than they have so far. I think that biosimilar manufacturers really need to better understand how the reference manufacturers are responding to biosimilars. Also, the limitations that limit our ability to force a step through of a biosimilar because of the different indications. It also limits our ability to put biosimilars in a similar place to the reference products. So, I think that they need to understand how we can best use biosimilars and achieve our cost savings." Medical Director Mid-sized national payer.
"I think the institutions, compared to the health plans, are having a much easier time converting to a biosimilar. The health plan may have contracts with a branded originator that may impede the need to go to a biosimilar. And what do you do with existing patients? So, it's perhaps easier to get new starts on a biosimilar. But two-thirds of your patients are stable and already on the branded product. We can try to create incentives to switch, at the patient's side or the provider's side. But that may be a very slow process, until we have interchangeability for the biosimilars. So, in the end we may actually do better by sticking with a branded originator, especially if there exists some discounting." Chief Medical Officer, Managed care.
"As a payer, if I am preferring adalimumab X, Y, Z instead of Humira and the pharmacy gets a prescription for Humira, they cannot automatically substitute the adalimumab that I prefer. Technically they have to pick up the phone, call the doctor and say, 'Humira is not covered for this patient, can we change it to adalimumab X, Y, Z?'" Pharmacy Director , Large PBM.
A detailed report exploring US payer insights on the obstacles facing the US biosimilars sector and the key developments which could drive wider adoption and use through:
Experts contributing to this report have been screened to ensure they have:
To ensure full and frank disclosure of opinion from experts, contributions have been anonymized.
FirstWord's ExpertViews reports reveal the real world insights of knowledgeable experts to analyze in detail key commercial and market trends that pharma management need to understand if they are to effectively respond to critical developments. These highly-focussed reports: